Tolga Tanguler Sells 1,754 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) EVP Tolga Tanguler sold 1,754 shares of the company’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $210.00, for a total transaction of $368,340.00. Following the sale, the executive vice president now owns 3,629 shares in the company, valued at $762,090. The sale was disclosed in a filing with the SEC, which is available at this link.
Tolga Tanguler also recently made the following trade(s):
- On Friday, August 5th, Tolga Tanguler sold 1,841 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $218.16, for a total transaction of $401,632.56.
- On Tuesday, July 5th, Tolga Tanguler sold 1,754 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $150.00, for a total transaction of $263,100.00.
Alnylam Pharmaceuticals Trading Down 2.4 %
NASDAQ:ALNY opened at $218.58 on Friday. The company has a 50-day moving average price of $145.22 and a 200-day moving average price of $147.96. Alnylam Pharmaceuticals, Inc. has a 12 month low of $117.58 and a 12 month high of $226.00. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 3.85. The stock has a market cap of $26.24 billion, a price-to-earnings ratio of -26.75 and a beta of 0.74.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.67). The business had revenue of $224.80 million during the quarter, compared to the consensus estimate of $256.06 million. Alnylam Pharmaceuticals had a negative return on equity of 204.18% and a negative net margin of 110.91%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.61) earnings per share. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -7.86 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on ALNY. SVB Leerink upped their target price on shares of Alnylam Pharmaceuticals from $96.00 to $98.00 and gave the stock a “market perform” rating in a report on Wednesday, June 15th. Chardan Capital increased their price target on shares of Alnylam Pharmaceuticals from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday. BMO Capital Markets increased their price target on shares of Alnylam Pharmaceuticals from $166.00 to $192.00 and gave the stock a “market perform” rating in a report on Thursday. Guggenheim lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, June 27th. Finally, William Blair assumed coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, June 7th. They issued an “outperform” rating on the stock. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $225.75.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ALNY. Capital World Investors increased its stake in shares of Alnylam Pharmaceuticals by 1,781.1% in the 1st quarter. Capital World Investors now owns 5,999,674 shares of the biopharmaceutical company’s stock worth $979,687,000 after acquiring an additional 5,680,728 shares in the last quarter. Norges Bank bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at about $215,229,000. Deep Track Capital LP increased its stake in Alnylam Pharmaceuticals by 4,062.9% during the 1st quarter. Deep Track Capital LP now owns 463,663 shares of the biopharmaceutical company’s stock valued at $75,712,000 after purchasing an additional 475,363 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Alnylam Pharmaceuticals by 17.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,997,762 shares of the biopharmaceutical company’s stock valued at $326,975,000 after purchasing an additional 295,092 shares in the last quarter. Finally, Eaton Vance Management increased its stake in Alnylam Pharmaceuticals by 606.7% during the 1st quarter. Eaton Vance Management now owns 306,228 shares of the biopharmaceutical company’s stock valued at $50,005,000 after purchasing an additional 262,893 shares in the last quarter. 92.39% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
Receive News & Ratings for Alnylam Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.